Supplementary Materials for Q3 Financial Results for the Fiscal Year Ending March 2026 – February 6

Performance Overview

Ordinary revenue for the third quarter of the fiscal year ending March 2026 was 54,995 million yen (10.6% increase Year-over-Year), with insurance underwriting revenue increasing by 9.8%. Investment income also performed strongly with a 47.6% increase, resulting in overall revenue growth. However, ordinary income before goodwill amortization was 2,422 million yen (39.1% decrease Year-over-Year), and ordinary income was 2,228 million yen (41.2% decrease Year-over-Year), showing a decline in profits. This was due to costs related to the transfer of contracts from AXA Direct and investments in JARVIS Tokyo. Net income also decreased to 1,426 million yen (44.6% decrease Year-over-Year).

Progress on Key Initiatives

In the insurance business, new contract acquisitions remained high at 67,000 contracts per quarter, pushing the total number of retained contracts past 1.37 million. The transfer of contracts from AXA Direct has been completed, with transfer fees trending downward. On the product and service side, steady growth continues in the “Animal Health” segment, maintaining a stable retention rate of 88.4%. Asset management is conducted flexibly and dynamically, achieving planned targets. Demand for advanced medical care remains robust, with JARVIS Animal Medical Center Tokyo showing 174% progress against plan.